BioSpace, News, Syndication »

Allergan Inc. Resolves United States Government Investigation of Past Sales and Marketing Practices Relating to Certain Therapeutic Uses of BOTOX(R)’ to Pay $375 Million to Government, Plus Another $225 In Civil Claims
Posted by BioSpace.com Featured News August 31st, 2010 .
No Comments

IRVINE, Calif., Sep 01, 2010 (BUSINESS WIRE) -- Allergan, Inc. /quotes/comstock/13*!agn/quotes/nls/agn (AGN 61.42, -0.59, -0.95%) today announced that it has reached a resolution with the United States Department of Justice (DOJ) regarding the previously reported Government investigation into Allergan's past U.S. sales and marketing practices relating to certain therapeutic uses of BOTOX(R) (onabotulinumtoxinA... More...

BioSpace, News, Syndication »

Allergan Inc. Receives FDA Approval for LUMIGAN(R) 0.01% as First-Line Therapy Indicated for the Reduction of Elevated Intraocular Pressure in Glaucoma Patients
Posted by BioSpace.com Featured News August 31st, 2010 .
No Comments

IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc. (NYSE:AGN - News) today announced the United States Food and Drug Administration (FDA) has approved LUMIGAN (bimatoprost ophthalmic solution) 0.01% as a first-line therapy indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. LUMIGAN 0.01% is an optimized reformulation of LUMIGAN... More...

BioSpace, News, Syndication »

Allergan Inc. To Pay $600 Mln To Settle Botox Probe
Posted by BioSpace.com Featured News August 31st, 2010 .
No Comments

IRVINE, Calif., Sep 01, 2010 (BUSINESS WIRE) -- Allergan, Inc. /quotes/comstock/13*!agn/quotes/nls/agn (AGN 61.42, -0.59, -0.95%) today announced that it has reached a resolution with the United States Department of Justice (DOJ) regarding the previously reported Government investigation into Allergan's past U.S. sales and marketing practices relating to certain therapeutic uses of BOTOX(R) (onabotulinumtoxinA... More...

BioSpace, News, Syndication »

Genzyme Corporation Release: Data from Mipomersen Phase 3 Trial in heFH Patients Presented at European Society of Cardiology
Posted by BioSpace.com Featured News August 31st, 2010 .
No Comments

CAMBRIDGE, Mass. & CARLSBAD, Calif.--(BUSINESS WIRE)--Genzyme Corp. (NASDAQ: GENZ) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) announced that data from the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) were presented today at the European Society of Cardiologys Congress 2010 in Stockholm, Sweden. The study met its primary endpoint with a 28 percent... More...

BioSpace, News, Syndication »

ReVision’s Fenretinide (RT-101) Reduced Incidence of Choroidal Neovascularization by More Than 50 Percent in Patients With Geographic Atrophy in a Phase 2b Trial
Posted by BioSpace.com Featured News August 31st, 2010 .
No Comments

SAN DIEGO, Sept. 1 /PRNewswire/ -- ReVision Therapeutics Inc. today announced that data from a Phase 2b trial show that fenretinide (RT-101) reduced the incidence of choroidal neovascularization (CNV, wet age related macular degeneration) by about 50 percent in patients with geographic atrophy (GA), the most advanced form of dry age related macular degeneration... More...

BioSpace, News, Syndication »

ISTA Pharmaceuticals, Inc. to Present at the Conference 2010
Posted by BioSpace.com Featured News August 31st, 2010 .
No Comments

IRVINE, Calif., Sept. 1 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced it will present at the Stifel Nicolaus Healthcare Conference 2010 at 11:30 a.m. Eastern Time on September 16, 2010, in Boston, MA. ISTA's President and Chief Executive... More...

BioSpace, News, Syndication »

Optimer Pharmaceuticals, Inc. to Present at September 2010 Investor Conferences
Posted by BioSpace.com Featured News August 31st, 2010 .
No Comments

SAN DIEGO, Sept. 1 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that the Company will present at the following investor conferences:

• Robert W. Baird 2010 Health Care Conference on Tuesday, September 14, 2010 at 8:30 a.m. Eastern Time at The... More...

BioSpace, News, Syndication »

ADVENTRX Pharmaceuticals Inc. to Present at The Rodman & Renshaw Annual Global Investment Conference on September 14
Posted by BioSpace.com Featured News August 31st, 2010 .
No Comments

SAN DIEGO, Sept. 1 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the Rodman & Renshaw Annual Global Investment Conference on Tuesday September 14, 2010 at <span class"xn-chron... More...

BioSpace, News, Syndication »

ReVision Therapeutics, Inc.’s Fenretinide (RT-101) Reduced Incidence of Choroidal Neovascularization by More Than 50 Percent in Patients With Geographic Atrophy in a Phase 2b Trial
Posted by BioSpace.com Featured News August 31st, 2010 .
No Comments

SAN DIEGO, Sept. 1 /PRNewswire/ -- ReVision Therapeutics Inc. today announced that data from a Phase 2b trial show that fenretinide (RT-101) reduced the incidence of choroidal neovascularization (CNV, wet age related macular degeneration) by about 50 percent in patients with geographic atrophy (GA), the most advanced form of dry age related macular degeneration... More...